医薬品製剤市場：剤形、技術、治療領域、エンドユーザー別-2025-2030年の世界予測

医薬品製剤市場は、2023年に2兆4,200億米ドルと評価され、2024年には2兆5,500億米ドルに達すると予測され、CAGR 5.70％で成長し、2030年には3兆5,600億米ドルに達すると予測されています。

医薬品製剤の対象範囲には、化学化合物を安全で効果的な医薬品として創製し、患者に使用することが含まれます。薬剤の組成、剤形、有効性、安定性、ドラッグデリバリー機構を決定することが含まれます。医薬品製剤の必要性は、バイオアベイラビリティを向上させ、安全性を確保し、薬剤の保存期間を延長する必要性から生じます。用途は医薬品、栄養補助食品、バイオテクノロジー業界全体に広がっており、最終用途は患者の治療ニーズ、動物用医薬品、臨床試験に重点が置かれています。主な成長要因としては、慢性疾患の増加、人口の高齢化、技術の進歩、製薬企業による研究開発費の増加などが挙げられます。最新の潜在的ビジネスチャンスは、ゲノムおよびプロテオミクス研究が牽引する個別化医療と生物製剤、および治療薬の有効性と標的を大幅に改善できるナノテクノロジーなどのドラッグデリバリーシステムの拡大にあります。こうした機会を捉えるためには、企業は研究開発協力に投資し、汎用性の高い製造プロセスを採用する必要があります。

しかし、複雑な規制の枠組み、高い開発コスト、医薬品製剤に関連しがちな長い承認プロセスなど、市場は手ごわい課題に直面しています。さらに、ジェネリック医薬品やバイオ医薬品との競合が市場成長の妨げとなる可能性もあります。これらの要因を考慮すると、技術革新は経口薄膜製剤や経皮吸収パッチ製剤など、送達システムを改善した製剤の開発に注力すべきです。環境に優しいプロセスや持続可能な手法の調査は、コスト効率を高め、環境基準の上昇に対応することにつながる可能性があります。医薬品製剤市場は、技術的・臨床的進歩に牽引されるダイナミックな市場であるが、規制の変更や経済情勢による外部からの圧力にさらされ続けています。成長を維持し競争力を獲得するためには、企業は戦略的パートナーシップを追求し、製剤開発にデジタル技術を取り入れ、適応性の高いドラッグデリバリーソリューションで新興国市場に対応すべきです。

市場力学：急速に進化する医薬品製剤市場の主要市場インサイトを公開

医薬品製剤市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の流行と効果的な治療の必要性
  • 医薬品開発・発見を奨励する政府の取り組み
  • 個別化医療やテーラーメイド医療の台頭
• 市場抑制要因
  • 医薬品・薬剤のリコール問題
• 市場機会
  • ドラッグデリバリーと投薬技術の進歩
  • ジェネリック医薬品開発のためのCDMOへの投資
• 市場の課題
  • 複雑な製剤開発と加工

ポーターのファイブフォース：医薬品製剤市場をナビゲートする戦略ツール

ポーターのファイブフォース」フレームワークは、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：医薬品製剤市場における外部からの影響の把握

外部マクロ環境要因は、医薬品製剤市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析医薬品製剤市場における競合情勢の把握

医薬品製剤市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス医薬品製剤市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、医薬品製剤市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨医薬品製剤市場における成功への道筋を描く

医薬品製剤市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の蔓延と効果的な治療の必要性
    • 医薬品の開発と発見を奨励する政府の取り組み
    • パーソナライズされた医療と治療法の台頭
  • 抑制要因
    • 医薬品の有害事象による回収
  • 機会
    • ドラッグデリバリーおよび投薬技術の進歩
    • ジェネリック医薬品開発のためのCDMOへの投資
  • 課題
    • 医薬品製剤の複雑な開発と処理
• 市場セグメンテーション分析
  • 剤形：慢性治療における経口剤の利便性と有効性
  • エンドユーザー：製薬会社による医薬品開発への投資増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 医薬品製剤市場剤形別

• 吸入製剤
  • ドライパウダー吸入器
  • ネブライザー
  • 加圧式定量吸入器
• 経口製剤
  • カプセル
  • グミ
  • ロゼンジとトローチ
  • 粉末・顆粒
  • タブレット
• 非経口製剤
  • エマルジョン
  • ジェル
  • 粉末
  • ソリューション
  • サスペンション
• 局所用製剤
  • クリーム、ローション、フォーム
  • ジェル、チンキ剤、パウダー
  • 軟膏とオイル
  • ペースト
  • スプレーとパッチ

第7章 医薬品製剤市場：技術別

• 即効性製剤
• リポソーム製剤
• マイクロスフィア製剤
• 放出調節製剤
• ナノ製剤
• 自己乳化型ドラッグデリバリーシステム
• 固体分散製剤

第8章 医薬品製剤市場治療領域別

• 心臓血管
• 中枢神経系
• 皮膚科
• 内分泌学
• 胃腸
• 免疫学
• 感染症
• 腫瘍学
• 眼科
• 疼痛管理
• 呼吸器

第9章 医薬品製剤市場：エンドユーザー別

• 学術・調査機関
• 契約開発および製造組織
• 病院・クリニック
• 製薬会社

第10章 南北アメリカの医薬品製剤市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の医薬品製剤市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの医薬品製剤市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • グレンマーク、インドの2型糖尿病患者向けにトリプル医薬品製剤を開始
  • ニューロクライン・バイオサイエンス社、米国FDAがINGREZZA（バルベナジン）経口顆粒スプリンクル製剤の新薬申請を受理したことを発表
  • メルクとXtalPiのコラボレーションにより、AIを活用した技術で医薬品の処方を最適化
• 戦略分析と提言

企業一覧

• 3M Company
• AbbVie Inc.
• Amgen, Inc.
• AstraZeneca plc.
• Bayer AG
• Boehringer Ingelheim International GmbH
• Boston Scientific Corporation
• Catalent, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Gerresheimer AG
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals Limited
• Halozyme Therapeutics, Inc.
• Johnson & Johnson Services, Inc.
• Marksans Pharma Ltd.
• Medicef Pharma
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Teva Pharmaceuticals Industries Ltd.
• The Bristol-Myers Squibb Company

LIST OF FIGURES

• FIGURE 1. DRUG FORMULATION MARKET RESEARCH PROCESS
• FIGURE 2. DRUG FORMULATION MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DRUG FORMULATION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. DRUG FORMULATION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. DRUG FORMULATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DRUG FORMULATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DRUG FORMULATION MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DRUG FORMULATION MARKET DYNAMICS
• TABLE 7. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DRUG FORMULATION MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DRUG FORMULATION MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DRUG FORMULATION MARKET SIZE, BY PRESSURIZED METERED DOSE INHALER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DRUG FORMULATION MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DRUG FORMULATION MARKET SIZE, BY GUMMIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DRUG FORMULATION MARKET SIZE, BY LOZENGES & PASTILLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDERS & GRANULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DRUG FORMULATION MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DRUG FORMULATION MARKET SIZE, BY EMULSIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DRUG FORMULATION MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DRUG FORMULATION MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL DRUG FORMULATION MARKET SIZE, BY CREAMS, LOTIONS, & FOAMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL DRUG FORMULATION MARKET SIZE, BY GELS, TINCTURES, & POWDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL DRUG FORMULATION MARKET SIZE, BY OINTMENTS & OILS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL DRUG FORMULATION MARKET SIZE, BY PASTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL DRUG FORMULATION MARKET SIZE, BY SPRAYS & PATCHES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL DRUG FORMULATION MARKET SIZE, BY IMMEDIATE-RELEASE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL DRUG FORMULATION MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL DRUG FORMULATION MARKET SIZE, BY MICROSPHERE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL DRUG FORMULATION MARKET SIZE, BY MODIFIED-RELEASE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL DRUG FORMULATION MARKET SIZE, BY NANOFORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL DRUG FORMULATION MARKET SIZE, BY SELF-EMULSIFYING DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLID DISPERSION FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL DRUG FORMULATION MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL DRUG FORMULATION MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL DRUG FORMULATION MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL DRUG FORMULATION MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL DRUG FORMULATION MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL DRUG FORMULATION MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL DRUG FORMULATION MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 53. GLOBAL DRUG FORMULATION MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 54. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. GLOBAL DRUG FORMULATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 56. GLOBAL DRUG FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 57. GLOBAL DRUG FORMULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 58. GLOBAL DRUG FORMULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 59. AMERICAS DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 60. AMERICAS DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 61. AMERICAS DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 62. AMERICAS DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 63. AMERICAS DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 64. AMERICAS DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 65. AMERICAS DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 66. AMERICAS DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 68. ARGENTINA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 69. ARGENTINA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 70. ARGENTINA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 71. ARGENTINA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 72. ARGENTINA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 73. ARGENTINA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 74. ARGENTINA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 75. ARGENTINA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. BRAZIL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 77. BRAZIL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 78. BRAZIL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 79. BRAZIL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 80. BRAZIL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 81. BRAZIL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 82. BRAZIL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 83. BRAZIL DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 84. CANADA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 85. CANADA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 86. CANADA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 87. CANADA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 88. CANADA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 89. CANADA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 90. CANADA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 91. CANADA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. MEXICO DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 93. MEXICO DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 94. MEXICO DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 95. MEXICO DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 96. MEXICO DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 97. MEXICO DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 98. MEXICO DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 99. MEXICO DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. UNITED STATES DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 101. UNITED STATES DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 102. UNITED STATES DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 103. UNITED STATES DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 104. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 105. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 106. UNITED STATES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 107. UNITED STATES DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 108. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 110. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 112. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 114. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 116. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 118. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 119. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 120. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 121. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 122. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 123. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 124. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 125. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. CHINA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 127. CHINA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 128. CHINA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 129. CHINA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 130. CHINA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 131. CHINA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 132. CHINA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 133. CHINA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. INDIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 135. INDIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 136. INDIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 137. INDIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 138. INDIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 139. INDIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 140. INDIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 141. INDIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. INDONESIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 143. INDONESIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 144. INDONESIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 145. INDONESIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 146. INDONESIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 147. INDONESIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 148. INDONESIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 149. INDONESIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 150. JAPAN DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 151. JAPAN DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 152. JAPAN DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 153. JAPAN DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 154. JAPAN DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 155. JAPAN DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 156. JAPAN DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 157. JAPAN DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 158. MALAYSIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 159. MALAYSIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 160. MALAYSIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 161. MALAYSIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 162. MALAYSIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 163. MALAYSIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 164. MALAYSIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 165. MALAYSIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 166. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 167. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 168. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 169. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 170. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 171. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 172. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 173. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 174. SINGAPORE DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 175. SINGAPORE DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 176. SINGAPORE DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 177. SINGAPORE DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 178. SINGAPORE DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 179. SINGAPORE DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 180. SINGAPORE DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 181. SINGAPORE DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 182. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 183. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 184. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 185. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 186. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 187. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 188. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 189. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 190. TAIWAN DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 191. TAIWAN DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 192. TAIWAN DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 193. TAIWAN DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 194. TAIWAN DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 195. TAIWAN DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 196. TAIWAN DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 197. TAIWAN DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 198. THAILAND DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 199. THAILAND DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 200. THAILAND DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 201. THAILAND DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 202. THAILAND DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 203. THAILAND DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 204. THAILAND DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 205. THAILAND DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 206. VIETNAM DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 207. VIETNAM DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 208. VIETNAM DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 209. VIETNAM DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 210. VIETNAM DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 211. VIETNAM DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 212. VIETNAM DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 213. VIETNAM DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 223. DENMARK DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 224. DENMARK DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 225. DENMARK DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 226. DENMARK DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 227. DENMARK DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 228. DENMARK DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 229. DENMARK DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 230. DENMARK DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 231. EGYPT DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 232. EGYPT DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 233. EGYPT DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 234. EGYPT DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 235. EGYPT DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 236. EGYPT DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 237. EGYPT DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 238. EGYPT DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 239. FINLAND DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 240. FINLAND DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 241. FINLAND DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 242. FINLAND DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 243. FINLAND DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 244. FINLAND DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 245. FINLAND DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 246. FINLAND DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 247. FRANCE DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 248. FRANCE DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 249. FRANCE DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 250. FRANCE DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 251. FRANCE DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 252. FRANCE DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 253. FRANCE DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 254. FRANCE DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 255. GERMANY DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 256. GERMANY DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 257. GERMANY DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 258. GERMANY DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 259. GERMANY DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 260. GERMANY DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 261. GERMANY DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 262. GERMANY DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 263. ISRAEL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 264. ISRAEL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 265. ISRAEL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 266. ISRAEL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 267. ISRAEL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 268. ISRAEL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 269. ISRAEL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 270. ISRAEL DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 271. ITALY DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 272. ITALY DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 273. ITALY DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 274. ITALY DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 275. ITALY DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 276. ITALY DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 277. ITALY DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 278. ITALY DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 279. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 280. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 281. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 282. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 283. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 284. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 285. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 286. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 287. NIGERIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 288. NIGERIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 289. NIGERIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 290. NIGERIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 291. NIGERIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 292. NIGERIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 293. NIGERIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 294. NIGERIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 295. NORWAY DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 296. NORWAY DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 297. NORWAY DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 298. NORWAY DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 299. NORWAY DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 300. NORWAY DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 301. NORWAY DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 302. NORWAY DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 303. POLAND DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 304. POLAND DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 305. POLAND DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 306. POLAND DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 307. POLAND DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 308. POLAND DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 309. POLAND DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 310. POLAND DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 311. QATAR DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 312. QATAR DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 313. QATAR DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 314. QATAR DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 315. QATAR DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 316. QATAR DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 317. QATAR DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 318. QATAR DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 319. RUSSIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 320. RUSSIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 321. RUSSIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 322. RUSSIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 323. RUSSIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 324. RUSSIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 325. RUSSIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 326. RUSSIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 327. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 328. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 329. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 330. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 331. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 332. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 333. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 334. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 335. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 336. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 337. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 338. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 339. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 340. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 341. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 342. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 343. SPAIN DRU

The Drug Formulation Market was valued at USD 2.42 trillion in 2023, expected to reach USD 2.55 trillion in 2024, and is projected to grow at a CAGR of 5.70%, to USD 3.56 trillion by 2030.

The scope of drug formulation encompasses the creation of chemical compounds into safe and effective drugs for patient use. It involves determining the drug's composition, dosage form, efficacy, stability, and delivery mechanism. The necessity for drug formulation arises from the requirement to enhance bioavailability, ensure safety, and extend the drug's shelf life. Applications are widespread across pharmaceuticals, nutritional supplements, and biotechnology industries, with end-use focused on patient therapeutic needs, veterinary medicine, and clinical trials. Key growth factors include rising chronic diseases, an aging population, technological advancements, and increased R&D expenditure by pharmaceutical companies. The latest potential opportunities lie in personalized medicine and biologics, driven by genomics and proteomics research, and the expansion of drug delivery systems such as nanotechnology, which can significantly improve the efficacy and targeting of therapeutic agents. To seize these opportunities, companies must invest in R&D collaborations and adopt versatile manufacturing processes.

However, the market faces formidable challenges, such as complex regulatory frameworks, high development costs, and the lengthy approval processes often associated with drug formulation. Furthermore, competition from generic drugs and biopharmaceuticals can hinder market growth. In light of these factors, innovation should focus on developing formulations with improved delivery systems, such as oral thin films and transdermal patches. Research in eco-friendly processes and sustainable practices could lead to cost efficiency and meet rising environmental standards. The drug formulation market is dynamic, driven by technological and clinical advancements, but remains subject to external pressures from regulatory changes and economic conditions. To maintain growth and gain competitive edge, companies should pursue strategic partnerships, embrace digital technologies for formulation development, and cater to emerging markets with adaptive drug delivery solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Drug Formulation Market

The Drug Formulation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of chronic diseases and need for effective treatments
  • Government initiatives encouraging drug development and discovery
  • Rise of personalized and tailored medicine and therapies
• Market Restraints
  • Adverse recalls of drugs and medications
• Market Opportunities
  • Advancements in drug delivery and dosage technologies
  • Investments in CDMOs to develop generic drugs
• Market Challenges
  • Complex development and processing of drug formulations

Porter's Five Forces: A Strategic Tool for Navigating the Drug Formulation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Drug Formulation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Drug Formulation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Drug Formulation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Drug Formulation Market

A detailed market share analysis in the Drug Formulation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Drug Formulation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Drug Formulation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Drug Formulation Market

A strategic analysis of the Drug Formulation Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Drug Formulation Market, highlighting leading vendors and their innovative profiles. These include 3M Company, AbbVie Inc., Amgen, Inc., AstraZeneca plc., Bayer AG, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Catalent, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Gerresheimer AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Halozyme Therapeutics, Inc., Johnson & Johnson Services, Inc., Marksans Pharma Ltd., Medicef Pharma, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceuticals Industries Ltd., and The Bristol-Myers Squibb Company.

Market Segmentation & Coverage

This research report categorizes the Drug Formulation Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Dosage Form, market is studied across Inhalation Formulations, Oral Formulations, Parenteral Formulations, and Topical Formulations. The Inhalation Formulations is further studied across Dry Powder Inhaler, Nebulizer, and Pressurized Metered Dose Inhaler. The Oral Formulations is further studied across Capsules, Gummies, Lozenges & Pastilles, Powders & Granules, and Tablets. The Parenteral Formulations is further studied across Emulsions, Gels, Powders, Solutions, and Suspensions. The Topical Formulations is further studied across Creams, Lotions, & Foams, Gels, Tinctures, & Powders, Ointments & Oils, Pastes, and Sprays & Patches.
• Based on Technology, market is studied across Immediate-Release Formulations, Liposomal Formulations, Microsphere Formulations, Modified-Release Formulations, Nanoformulations, Self-Emulsifying Drug Delivery Systems, and Solid Dispersion Formulations.
• Based on Therapeutic Area, market is studied across Cardiovascular, Central Nervous System, Dermatology, Endocrinology, Gastrointestinal, Immunology, Infectious Diseases, Oncology, Ophthalmology, Pain Management, and Respiratory.
• Based on End User, market is studied across Academic & Research Institutions, Contract Development & Manufacturing Organizations, Hospitals & Clinics, and Pharmaceutical Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of chronic diseases and need for effective treatments
    • 5.1.1.2. Government initiatives encouraging drug development and discovery
    • 5.1.1.3. Rise of personalized and tailored medicine and therapies
  • 5.1.2. Restraints
    • 5.1.2.1. Adverse recalls of drugs and medications
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in drug delivery and dosage technologies
    • 5.1.3.2. Investments in CDMOs to develop generic drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Complex development and processing of drug formulations
• 5.2. Market Segmentation Analysis
  • 5.2.1. Dosage Form: Convenience and effectiveness of oral formulations for chronic treatments
  • 5.2.2. End User: Rising investments in drug developments by pharmaceutical companies
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Drug Formulation Market, by Dosage Form

• 6.1. Introduction
• 6.2. Inhalation Formulations
  • 6.2.1. Dry Powder Inhaler
  • 6.2.2. Nebulizer
  • 6.2.3. Pressurized Metered Dose Inhaler
• 6.3. Oral Formulations
  • 6.3.1. Capsules
  • 6.3.2. Gummies
  • 6.3.3. Lozenges & Pastilles
  • 6.3.4. Powders & Granules
  • 6.3.5. Tablets
• 6.4. Parenteral Formulations
  • 6.4.1. Emulsions
  • 6.4.2. Gels
  • 6.4.3. Powders
  • 6.4.4. Solutions
  • 6.4.5. Suspensions
• 6.5. Topical Formulations
  • 6.5.1. Creams, Lotions, & Foams
  • 6.5.2. Gels, Tinctures, & Powders
  • 6.5.3. Ointments & Oils
  • 6.5.4. Pastes
  • 6.5.5. Sprays & Patches

7. Drug Formulation Market, by Technology

• 7.1. Introduction
• 7.2. Immediate-Release Formulations
• 7.3. Liposomal Formulations
• 7.4. Microsphere Formulations
• 7.5. Modified-Release Formulations
• 7.6. Nanoformulations
• 7.7. Self-Emulsifying Drug Delivery Systems
• 7.8. Solid Dispersion Formulations

8. Drug Formulation Market, by Therapeutic Area

• 8.1. Introduction
• 8.2. Cardiovascular
• 8.3. Central Nervous System
• 8.4. Dermatology
• 8.5. Endocrinology
• 8.6. Gastrointestinal
• 8.7. Immunology
• 8.8. Infectious Diseases
• 8.9. Oncology
• 8.10. Ophthalmology
• 8.11. Pain Management
• 8.12. Respiratory

9. Drug Formulation Market, by End User

• 9.1. Introduction
• 9.2. Academic & Research Institutions
• 9.3. Contract Development & Manufacturing Organizations
• 9.4. Hospitals & Clinics
• 9.5. Pharmaceutical Companies

10. Americas Drug Formulation Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Drug Formulation Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Drug Formulation Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Glenmark Launches Triple Drug Formulation for Type 2 Diabetes Patients in India
  • 13.3.2. Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA (valbenazine) Oral Granules Sprinkle Formulation
  • 13.3.3. Merck & XtalPi Collaboration Optimizes Drug Formulations with AI-Powered Techniques
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 3M Company
• 2. AbbVie Inc.
• 3. Amgen, Inc.
• 4. AstraZeneca plc.
• 5. Bayer AG
• 6. Boehringer Ingelheim International GmbH
• 7. Boston Scientific Corporation
• 8. Catalent, Inc.
• 9. Eli Lilly and Company
• 10. F. Hoffmann-La Roche AG
• 11. Gerresheimer AG
• 12. Gilead Sciences, Inc.
• 13. GlaxoSmithKline plc
• 14. Glenmark Pharmaceuticals Limited
• 15. Halozyme Therapeutics, Inc.
• 16. Johnson & Johnson Services, Inc.
• 17. Marksans Pharma Ltd.
• 18. Medicef Pharma
• 19. Merck & Co., Inc.
• 20. Novartis AG
• 21. Pfizer Inc.
• 22. Sanofi SA
• 23. Teva Pharmaceuticals Industries Ltd.
• 24. The Bristol-Myers Squibb Company